• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Filgotinib effectively induces and maintains clinical remission in patients with ulcerative colitis

byNeel MistryandTeddy Guo
July 9, 2021
in Chronic Disease, Gastroenterology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the placebo group.

2. The proportion of patients with treatment-related side effects was similar between filgotinib 100 mg, filgotinib 200 mg, and placebo.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Ulcerative colitis (UC) is a chronic immune-mediated disease, marked by inflammation of the colon. Although Janus kinase (JAK) inhibitors, such as tofacitinib, have shown promise for treatment of UC, selective JAK-inhibitors may potentially offer comparable efficacies with fewer side-effects. While filgotinib, a JAK1-selective inhibitor, has demonstrated efficacy in conditions such as rheumatoid arthritis and ankylosing spondylitis, its efficacy for UC is uncertain. This randomized controlled trial aimed to assess the efficacy and safety of filgotinib in inducing and maintaining remission for patients with UC. Primary outcome for this study was clinical remission at weeks 10 and 58, defined by total Mayo Clinic Score (MCS), while key secondary outcomes included endoscopic, histologic, and 6-month corticosteroid-free remission. Safety was assessed in all patients receiving one or more dose of filgotinib within induction and maintenance studies. Compared to placebo, filgotinib 200 mg greatly induced and maintained clinical remission at weeks 10 and 58 in patients with moderate-to-severe UC. A longer follow-up would better inform best practices in the management of ulcerative colitis, a chronic inflammatory condition. Nevertheless, this study provided valuable insight into the use of filgotinib 200 mg once daily for management of UC.

Click to read the study in The Lancet

Relevant Reading: Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

RELATED REPORTS

Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

In-depth [randomized controlled trial]: Between Nov 14, 2016, and Mar 31, 2020, 2040 patients were assessed for eligibility at 341 study centers in 40 countries. Included patients were aged 18-75 years with moderate-to-severe UC for ≥ 6 months (total Mayo Clinic Score 6-12). Those who previously received any JAK inhibitor were excluded. Altogether, 625 patients in induction study A (237 in filgotinib 200 mg, 260 in filgotinib 100 mg, and 128 in placebo) and 635 patients in induction study B (242 in filgotinib 200 mg, 265 in filgotinib 100 mg, and 128 in placebo) completed study to week 10. Baseline characteristics were similar between treatment groups.

The primary outcome of clinical remission was greater for filgotinib 200 mg than placebo. This was true at week 10 (induction study A: 26.1% vs. 15.3%, 95% confidence interval [CI] 2.1-19.5, p=0.0157; induction study B: 11.5% vs. 4.2%, 95% CI 1.6-12.8, p<0.05) and week 58 (37.2% in filgotinib 200 mg vs. 11.2% in placebo, 95% CI 16.0-35.9, p<0.05) from baseline. When comparing clinical remission between filgotinib 100 mg and placebo, the difference was not significant at week 10 (p=0.33). However, by week 58, a significant difference was noted between groups, favouring filgotinib 100 mg (23.8% vs. 13.5%, 95% CI 0.0-20.7, p<0.05). The incidence of serious adverse events and adverse events of interest was similar between the three groups (4.3% for filgotinib 200 mg vs. 5.0% for filgotinib 100 mg vs. 4.7% for placebo). Findings from this study suggest that filgotinib 200 mg is more effective than filgotinib 100 mg and placebo for clinical remission in patients with moderate-to-severe ulcerative colitis.

Image: PD 

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Crohn's Diseasefilgotinibinflammatory bowel diseaseinflammatory bowel disease (IBD)inflammatory diseaseJAK inhibitorJAK1 inhibitorJanus kinase (JAK) inhibitorUlcerative Colitis
Previous Post

Study highlights trends and outcomes of bronchodilator use in infants with bronchiolitis

Next Post

#VisualAbstract Head and neck melanomas have high-local recurrence risk features and require more frequent tissue-rearranging reconstruction than basal cell and squamous cell carcinomas

RelatedReports

Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Rectoscopy alone may be sufficient to evaluate for remission of ulcerative colitis

June 9, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Both intestinal ultrasound and magnetic resonance imaging can assess radiologic stricturing in Crohn’s disease

May 14, 2025
Elective colectomy associated with improved survival in ulcerative colitis
Chronic Disease

Inflammatory bowel disease may be associated with increased risk of osteoporosis and osteopeia

April 17, 2025
Anti-TNF therapy for inflammatory bowel disease may induce skin lesions
Chronic Disease

Mirikizumab is safe and effective in patients with moderate-to-severe Crohn’s disease

February 6, 2025
Next Post
#VisualAbstract Head and neck melanomas have high-local recurrence risk features and require more frequent tissue-rearranging reconstruction than basal cell and squamous cell carcinomas

#VisualAbstract Head and neck melanomas have high-local recurrence risk features and require more frequent tissue-rearranging reconstruction than basal cell and squamous cell carcinomas

#VisualAbstract Obesity and body weight was not correlated with survival outcomes in patients with relapsed/refractory large B-cell lymphoma treated with CAR T-Cell therapy

#VisualAbstract Obesity and body weight was not correlated with survival outcomes in patients with relapsed/refractory large B-cell lymphoma treated with CAR T-Cell therapy

2 Minute Medicine Rewind July 12, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
  • Minimally invasive surgery is beneficial for epithelial ovarian cancer 
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.